Abstract
INTRODUCTION
Dilated cardiomyopathy (DCM) is a cardiac muscle disorder characterized by bilateral cardiac chamber enlargement and myocardial contractile dysfunction. 1 The clinical manifestations of this disease include progressive congestive heart failure, cardiac arrhythmia, thromboembolism, and even sudden death. 1 Currently, DCM has a poor prognosis because no effective therapies are available to cure it. Traditional Chinese medicine (TCM), which is based on symptom pattern identification and global concept, has emerged as a potentially effective treatment for cardiovascular diseases including DCM. The TCM diagnosis and treatment of heart swelling published by the State Administration of Traditional Chinese Medicine has identified the Qi-Yin deficiency pattern as one of the common patterns of DCM.
2 Consistent with this finding, we found that Qi-Yin deficiency and blood stasis are common in the clinical setting. Therefore, based on the "Yiqi Yangyi Huoxue" principle, we produced Shenqi Yangxin decoction (SQYXD) following the guidelines of the theory and practice of TCM. Early clinical observations confirmed that SQYXD effectively alleviates the clinical symptoms of DCM patients and improves heart function, however the underlying molecular basis is unknown. The present study was designed to investigate the effects of SQYXD on heart function in a rat model of DCM induced by adriamycin. We further explored its underlying mechanism of action in the treatment of DCM.
MATERIALS AND METHODS

Animals
All animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, and the animal protocol was approved by the Animal Care and Use Committee at the Institute of Nanjing University of Chinese Medicine. A total of 160 male Sprague Dawley rats [8 weeks old and weighing 260-280 g; Beijing SCXK Laboratory Animal Co., Ltd. (Beijing, China)] were used in this study.
Experimental drugs
Doxorubicin hydrochloride (10 mg/bottle), was purchased from Shenzhen Main Luck Pharmaceutical Co., Ltd. (Shenzhen, China). Perindopril tablets (Yashida, 4 mg/tablet, 30 tablets/box), were purchased from Servier Pharmaceutical Co., Ltd. (Tianjin, China). Metoprolol tablets (bettarox, 25 mg/tablet, 20 tablets/box), were purchased from AstraZeneca Pharmaceutical Co., Ltd. (Wuxi, China). Shenqi Yangxin Tang: all Chinese medicine were granules were purchased from Jiangsu Tianjiang Pharmaceutical Co., Ltd. (Wuxi, China).
Generation of animal model and grouping
Sprague-Darley rats were randomly divided into the normal group (10 rats) and DCM group (150 rats). Adriamycin-induced DCM was generated as described previously. 3 Briefly, 150 rats were intraperitoneally injected with adriamycin (1 mg/kg, twice per week) for 6 weeks, and observed for 2 weeks. Ten rats were randomly selected to confirm that model was successfully established. Sixteen rats were randomly selected as the DCM baseline (used to confirm the induction of dilated cardiomyopathy). The remaining model rats were randomly divided into DCM control, perindopril, metoprolol, and SQYXD groups. The rats of the DCM control group were gavaged with an equal volume of saline. During the treatment period, the survival rate of the rats was observed daily.
Treatment
Perindopril group: the rats of this group were gavaged with perindopril superfine powder at a dosage of 3 mg· kg
Metoprolol group: the rats of this group were gavaged with metoprolol (25 mg/rat, Metoprolol tablets at a dosage of 50 mg/kg twice a day for 8 weeks (a quarter of the total dose was gavaged in the first week, and half of the total dose was gavaged in the second week (the initial dose was 12.5 mg/kg, and the weekly dose was adjusted from 50 mg/kg twice a day until a full weekly dosage was reached). During the treatment period, the general appearance, behavior, body weight, and survival rate of the rats were observed daily.
Echocardiography
Echocardiography was performed to assess cardiac morphology and function using a Philips CX50 ultrasound with a 12-MHz transducer. A parasternal short-axis view in the middle of the left ventricle at the level of the papillary muscles was used for analysis. The left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular fractional shortening (LVFS) and left ventricular ejection fraction (LVEF) were measured. For each variable, images from three cardiac cycles were analyzed and averaged for each mouse.
Blood and tissue sample preparation
Twelve hours after echocardiography acquisition, the animals were euthanized, and the uncoagulated blood was collected from the orbital venous plexus. Hearts were arrested in diastole by an intravenous injection of KCl (2 M). The hearts were removed, rinsed with saline, drained, and the atrium, ventricular septum and right ventricle removed to obtain the left ventricular myocardium. The excised myocardium was sliced into four blocks, two of which were preserved at -80 ℃ for measurement of mRNA and protein, one of which was fixed in 4% paraformaldehyde for 16-18 h at 4 ℃ followed by embedding in paraffin wax and cutting into 5-μm slices for subsequent histological analysis, and one of which was fixed in glutaraldehyde for electron microscopic observation.
Tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10), C-reactive protein (CRP) and serum BNP Blood samples were centrifuged at 13 000 rpm for 10 min, and serum was collected and stored at -80 ℃. Serum TNF-α, IL-1, IL-6, IL-10, CRP and BNP concentrations were measured by enzyme-linked immunosorbent assays (ELISAs) (Blue Base Biological Technology Co., Ltd., Shanghai, China), according to manufacturer's instructions.
Measurement of mRNA
The real-time polymerase chain reaction (PCR) was performed to measure high-mobility group box 1 (HMGB1), Toll-like receptor 4 (TLR-4), receptor for advanced glycation end products (RAGE), and nuclear factor-κB (NF-κB) levels as described previously. 7 The housekeeping gene β-actin was used as an internal control. The sequences of oligonucleotides used in this study are given in Table 1 . Samples underwent 95 ℃ denaturation for 60 s, followed by 45 cycles of 95 ℃ denaturation for 10 s, and 60 ℃ annealing and extension for 60 s. Relative quantitative analysis was carried out by using Light Cycler Relative quantification (Version 1.5) software, using the 2 -△△CT formula.
Measurement of protein expression
Western blot was performed as described previously. 8 18 Fluorodeoxyglucose-positron emission tomography/ computed tomography (FDG-PET/CT) for myocardial metabolism imaging was provided by the Department of Nuclear Medicine of the Fourth People's Hospital of Wuxi. The Siemens Inveon P120 PET scanner (Siemens, Munich, Germany) was used for PET imaging in this study. Briefly, rats were fasted, and water was withheld for 8 h before imaging to prevent interference from glucose during the imaging. After placement of a catheter into the tail vein, the rats were anesthetized with 10% chloral hydrate (3 mL/kg, i.p.), positioned in the prone position within the PET scanner, and kept warm on a heating pad to maintain the core body temperature at 37 ℃ , which was obtained through continuous monitoring of the rectal temperature. After intravenous administration of 2-deoxy-2-( (19 ± 5) MBq], the electrocardiogram-gated emission was recorded at 60-90 min after tracer injection, and a 7-min transmission scan was obtained to assess myocardial viability, as described previously. 6 The standard uptake value (SUV) was defined using the following formula: intensity of radioactivity of region of interest (MBq/mL) / radioactivity intensity of the region of interest (MBq) / body weight (g).
Statistical analysis
All data were processed with SPSS 21.0 (IBM SPSS Statistics for Windows, IBM Corp., Armonk, NY, USA) and expressed as the mean ± standard deviation ( x ± s). Kaplan-Meier analysis was used to determine the difference in survival rates among groups. Numerical data were analyzed using one-way analysis of variance. When a statistically significant difference was observed among groups, the least significant difference test or Dunnett's test was performed. Correlation analysis was analyzed by Pearson's correlation analysis. A P value less than 0.05 was considered to indicate a statistically significant difference.
RESULTS
Survival rate
Forty-one (27.3%) of the 150 model rats died between days 14 and 40, beginning 2 weeks after cessation of doxorubicin injection. In total 83 rats were involved in the drug intervention experiment. First, we examined the survival rates of rats in each group after completion of the 8-week treatment. As shown in Figure 1 , while the normal group did not show any deaths as expected, the cumulative survival rates were 95.0% (19/20) , 85.0% (17/20) , 90.0% (18/20) , and 69.6% (16/23) for the perindopril, metoprolol, SQYXD, and DCM control groups, respectively. In the DCM control group, 50% (8/16) of the remaining rats had ascites. The survival rate of the SQYXD group (90% ) was higher than the metoprolol group (85% ), but lower than the perindopril group (95%), no statistical significance was detected (P > 0.05).
Cardiac function
The rats in the DCM control group exhibited significantly decreased LVEF and LVFS values and increased LVEDD and LVESD values, compared with the normal control group, indicating impaired cardiac function. Compared with the DCM group, the perindopril, metoprolol, and SQYXD groups showed lower LVEDD and LVESD values (F = 27.972, P < 0.001; F = 33.281, P < 0.001) and higher LVEF and LVFS values (F = 22.798, P < 0.001; F = 39.423, P < 0.001) ( Table 1) . No significant differences in these indices between the three treatment groups were detected. These findings indicate that SQYXD treatment improved cardiac function in DCM rats as effectively as the other two treatments, as shown in Table 2 .
Heart weight (HW) index and serum BNP During the 8-week treatment period, the body weight of rats in the normal group significantly increased, compared with those in the other DCM groups. In contrast, in the DCM control and other treatment groups, no significant difference in the body weight was observed. However, DCM control rats had a substantially elevated HW/ body weight (BW) ratio, compared with the normal group; however, this increase was greatly reduced by the respective treatments. No significant difference in the HW/BW ratio between the three treatment groups was observed. The serum levels of BNP in the DCM control group rats were significantly higher than those in the normal group (P < 0.001), indicating myocardial injury. However, these increases in HW/BW ratio and BNP were substantially decreased by treatment (F = 24.840, P < 0.001; and F = 14.524, P < 0.001, respectively), suggesting alleviation of myocardial injury after treatment. No significant differences in the serum levels of BNP between the three treatment groups were seen (P > 0.05, Table 3 ).
Cardiac structure by hematoxylin-eosin (HE) staining
Compared with the normal group, the DCM control group showed extensive pathological changes, including cardiomyocyte vacuolization, degeneration, interstitial edema, and inflammatory cell infiltration. Notably, treatment with perindopril, metoprolol, or SQYXD ameliorated the histological damage induced by adriamycin, as revealed by HE staining (Figure 2 ). Cardiac structure by electron microscopy Consistent with the HE findings, electron microscopy revealed disorganized sarcomeres of cardiac muscles, swollen mitochondria, and vacuolar degeneration in the DCM control group, compared with the normal group, while all the pathological changes in the ultrastructure were improved by treatment with the respective drugs (Figure 3 ).
Myocardial metabolism
As expected, the myocardial glucose metabolism and myocardial 18 F-FDG uptake were significantly reduced in the DMC control group compared with normal group, and this reduction was significantly improved by SQYXD treatment (F = 15.67, P < 0.001, Figure 4 , Table 4 ). Myocardial mRNA expression of HMGB1, TLR-4, RAGE, and NF-κB As shown in Table 5 , the expression of HMGB1, TLR-4, RAGE, NF-κB at the mRNA level was significantly elevated in the DCM group, compared with that in the normal group. However, this elevation was substantially suppressed by SQYXD, perindopril and metoprolol treatment (F = 5.684, P < 0.001; F = 5.215, P = 0.001; F = 3.579, P = 0.009; F = 4.705, P = 0.002 respectively). No significant differences in the expression of SQYXD were detected between the three treatment groups. Thus, SQYXD inhibits the increase of HMGB1, TLR-4, RAGE, and NF-κB mRNA levels in the myocardium of DCM rats.
Correlation between the mRNA levels of HMGB1 and TLR-4, RAGE and NF-κB
The mRNA level of HMGB1 in the myocardium of the baseline group was positively correlated with the expression of TLR-4, RAGE, and NF-κB (r = 0.904, P < 0.000; R = 0.952, P < 0.000; r = 0.909, P = 0.002, respectively, Figure 5) . 
Correlation between the mRNA levels of HMGB1 and BNP, LVEDD, LVEF
The mRNA level of HMGB1 in the myocardium of the baseline group was positively correlated with BNP and LVEDD (r = 0.850, P = 0.003; r = 0.916, P = 0.001, Figure 6 ), but negatively correlated with LVEF (r = 0.880, P = 0.001, Figure 6 ).
Myocardial expression of HMGB1, TLR-4, RAGE, and NF-κB at the protein level
The protein expression of HMGB1, TLR-4, RAGE, and NF-κB was significantly elevated in the DCM group, compared with that in the normal group. Interestingly, this elevation was substantially suppressed by SQYXD, perindopril and metoprolol treatment. Compared with the Perindopril and Metoprolol group, SQYXD strongly inhibited the increase of HMGB1, TLR-4, RAGE, and NF-κB expression in the myocardium of DCM rats ( Figure 7 , Table 6 ).
Myocardial expression of proinflammatory cytokines
The expression of TNF-α, IL-1, IL-6, IL-10, and CRP was significantly elevated in the DCM group, compared with that in the normal group, which was substantially suppressed by SQYXD, perindopril and metoprolol treatment (F = 9.365, P < 0.001; F = 15.387, P < 0.001; F = 8.490, P < 0.001; F = 7.40, P < 0.001; F = 14.52, P < 0.001 respectively). No significant differences in the expression of proinflammatory cytokines were detected between the three treatment groups (Table 7) .
DISCUSSION
Currently, DCM has a poor prognosis because no effec- Table 5 Consistent with this finding, we found that the patterns of Qi-Yin deficiency and blood stasis are common in the clinical setting. Therefore, based on the "Yiqi Yangyin Huoxue" principle, we produced Shenqi Yangxin decoction (SQYXD) under the guidelines of the theory and practice of TCM. It has beneficial effects on Qi, Yin and blood. Early clinical observations have confirmed that SQYXD effectively alleviates the clinical symptoms of DCM patients and improves heart function, but the underlying molecular basis is unknown. In the diagnosis and treatment of DCM, cardiac ultrasound and BNP are the main means of auxiliary examination, which can assess the cardiac cavity and cardiac function. 9 PET myocardial metabolic imaging is an imaging technique that evaluates myocardial metabolism from a molecular level in vivo and is the gold standard for assessing myocardial viability. 10 Previously, a large number of studies were used to detect viable myocardium after myocardial infarction in coronary heart dis- Table 7 ease, 11 and to predict the recovery of LV function after revascularization. 12, 18 F-FDG PET has been rarely used in DCM. Our previous experiments show that 18 F-FDG PET can be used as a valuable tool for evaluating DCM models. 13 Because of its merits, include detection of the survival of myocardium in vivo, it can be used for the evaluation of curative efficacy. In the present study, the DCM model group had significantly enlarged cardiac cavities, heart failure, myocardial injury, abnormal myocardial glucose metabolism, decreased myocardial activity, and necrosis of myocardial cells. Thus, the animal model of DCM was successfully established. Previous studies have shown that supplementing Qi and nourishing Yin and promoting blood circulation for removing blood stasis with an herbal preparation for significantly inhibits myocardial cell apoptosis and alleviates a series of immune reactions due to apoptosis, improves the function of myocardial cells, thus contributing to the early treatment of DCM.
14 Consistent with the above findings, in the present study, we demonstrated that SQYXD can effectively reduce LVEDD and LVESD, improve LVEF and FS in DCM model rats; it also can inhibit the increased HWI, decrease the serum BNP levels of DCM rats, improve myocardial histomorphology and glucose metabolism. This suggests that SQYXD could reduce the degree of myocardial hypertrophy, inhibit heart enlargement, delay myocardial injury, and improve myocardial activity in DCM rats. HMGB1, a nonhistone nuclear factor, exhibits proinflammatory properties. HMGB-1 can be secreted by activated cells or released extracellularly by damaged cells; in addition, it may serve as an early promoter (released by necrotic cells) and facilitator (secreted by macrophages) of inflammation. 15, 16 Receptors of extracellular HMGB1 include receptor for RAGE and TLR. The combination of HMGB1 with RAGE or TLR can cause various inflammatory responses, tissue regeneration and heart failure. [17] [18] [19] Inflammation is prevalent in patients with heart failure and is a predictor of poor prognosis. 20 Isolated cardiomyocytes that were treated with HMGB1 for a few minutes showed decreased myofibrillar contractility by 70% , suggesting that HMGB1 is involved in the development of heart failure, and accelerated heart function decline. 20 The negative contraction of HMGB1 is associated with RAGE and TLR4. 20 Additionally, a clinical observation has demonstrated that the plasma HMGB1 level was significantly increased in patients with heart failure and was closely related to the severity of heart failure, indicating that HMGB1 may function as an inflammatory mediator in the inflammatory process of heart failure. 21 Importantly, there is little research on the relationship between HMGB1 and DCM. Clinical studies have shown that HMGB1 and its associated cytokines (TNF-α, IL-6) may be involved in the pathophysiological processes of DCM. 22 However, there are no report indicating which receptor HMGB1 acts through to activate the downstream signaling pathway in the development of DCM. In the present study, the expression of HMGB1 in DCM rats was higher than that in normal group, and HMGB1 was positively correlated with BNP level and LVEDD, and negatively correlated with LVEF. This is consistent with the above findings, suggesting that HMGB1 is involved in the development of DCM. The expression of TLR-4, RAGE and NF-κB in DCM rats was also higher than that in normal group, and HMGB1 was positively correlated with TLR-4, RAGE and NF-κB, suggesting that HMGB1 was involved in the DCM pathophysiological process via binding TLR-4 or RAGE, activation of NF-κB, promoting subsequent cytokine and inflammatory mediator release, which mediates cardiomyocyte injury, eventually leading to cardiac enlargement, and heart failure. Many studies have shown that TCM can not only effectively suppress HMGB1 and subsequent inflammation but also adjust the immune status of patients, to improve the symptoms and signs of patients. SQYXD is an effective prescription for the treatment of DCM. Early clinical observations have confirmed that SQYXD effectively alleviates the clinical symptoms of DCM patients and improves heart function. The results showed that SQYXD could decrease the expression of HMGB1, TLR-4, RAGE, and NF-κB at both the gene and protein level in DCM rats and improve the expression of TNF-α, IL-6, IL-10, and CRP in DCM rats. Previous studies found that metoprolol reduced the serum level of TNF-α and improved cardiac function in patients; 23 while perindopril reduced serum levels of inflammatory cytokines (TNF-α, IL-6), and improved cardiac function, 24 both studies suggesting downstream inflammatory cytokines play a role in DCM. The results of the current study show that, unlike metoprolol and perindopril, SQYXD plays a role upstream of the HMGB1 inflammatory signaling pathway, slowing the expansion of the heart, reducing the inner diameter of the left ventricular cavity and improving heart function. Therefore, we speculate that the mechanism of SQYXD on DCM may be related to its ability to reduce the expression of HMGB1 and its inflammatory signaling pathway. First, SQYXD can decrease the expression of HMGB1 in the myocardium of DCM rats, which blocks its association with TLR-4 or RAGE, blocking the activation of downstream inflammatory signaling pathway, inhibiting the inflammatory reaction and improving the myocardium remodeling and myocardial injury, alleviated myocardial dysfunction. Second, SQYXD can reduce the expression of cytokines and inflammatory mediators in DCM rats, thus blocking the cytokines which activate HMGB1 expression and initiation of the vicious proinflammatory cycle.
In conclusion, SQYXD improved the myocardial inflammatory response and myocardial systolic function through multi-target therapeutic effects, slowing the enlargement of the heart cavity, improving myocardial metabolic activity, and improving heart function in DCM.
